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Abstract Patients with type 1 diabetes (T1D) suffer excess
mortality from cardiovascular disease (CVD) that has
persisted despite substantial reductions in microvascular com-
plications. Although T1D and type 2 diabetes (T2D) are etio-
logically distinct, it has generally been assumed that CVD in
T1D is Bthe same disease^ as that found in T2D. Here, we
review the most recent epidemiological and clinical studies
on heart disease in T1D, highlighting differences between
CVD in T1D and T2D. In addition, we discuss experimental
and clinical evidence for a post-myocardial infarction (MI)
autoimmune heart syndrome in T1D, including the develop-
ment of diagnostic assays which we believe can, for the first
time, differentiate between heart disease in T1D and T2D. We
postulate that a clinically unrecognized form of chronic myo-
cardial inflammation (Bmyocarditis^) triggered byMI contrib-
utes to the poor CVD outcomes in T1D. These findings pro-
vide a conceptual shift in our understanding of CVD in T1D
and have important diagnostic and therapeutic implications.
Keywords Type 1 diabetes . Cardiovascular disease .
Myocardial infarction .Myocarditis . Heart failure .
Cardiomyopathy . Autoimmunity . Immune tolerance
Introduction
Cardiovascular disease (CVD) is the major cause of death in
diabetes. Although CVD most commonly occurs in type 2
diabetes [1], which is far more prevalent than T1D, the risk
of death from CVD is actually higher in T1D than in T2D [2].
This often under-appreciated excess CVD mortality in T1D is
remarkable in occurring at a relatively young age, with the
burden particularly striking for women [3, 4••]. Although the
Diabetes Control and Complications Trial (DCCT)/Epidemi-
ology of Diabetes Interventions and Complications (EDIC)
Study clearly established poor glycemic control as a key me-
diator of CVD risk in T1D [5], hyperglycemia only explains a
fraction of the overall risk [6]. While numerous factors related
to diabetes have been implicated, none have been unique to
T1D [7, 8]. In the absence of knowledge of disease-specific
mechanisms, designing appropriate interventions and strate-
gies for prevention of CVD in T1D has been problematic.
Indeed, current management approaches of CVD in T1D have
been largely extrapolated from experience in T2D [9••].
Although most published work on CVD has been focused
on the role of inflammation in atherosclerosis [9••, 10, 11], this
review will focus instead on the novel role of inflammation—
specifically due to autoimmunity—as a potential mediator of
cardiac dysfunction and heart failure in T1D [12••, 13••]. We
will discuss our findings indicating that the same defects in the
immune system that confer risk for T1D, also confer suscep-
tibility to chronic myocarditis (chronic inflammation of heart
muscle tissue) following a myocardial infarction (MI) and
thereby may contribute to excessively poor CVD outcomes
in T1D [12••, 14]. As a preliminary to these discussions, we
will present an overview of recent epidemiological and clini-
cal studies that have specifically focused on heart disease in
T1D. We will then summarize differences between the patho-
genesis of T1D and T2D with regard to CVD. We will then
This article is part of the Topical Collection onDiabetes, Other Diseases,
and New Complications: Emerging Associations
M. A. Lipes (*) :A. Galderisi
Joslin Diabetes Center, Harvard Medical School, 1 Joslin Place,
Rm. 373, Boston, MA 02215, USA
e-mail: myra.lipes@joslin.harvard.edu
A. Galderisi
Department of Woman’s and Child’s Health, University of Padua,
Via Giustiniani, 3, 35128 Padova, Italy
Curr Diab Rep  (2015) 15:30 
DOI 10.1007/s11892-015-0598-1
discuss how, starting with a serendipitous discovery in T1D-
humanized mice [15], we generated a diverse body of findings
that support an autoimmune Bdriver^ for post-MI damage in
T1D [12••, 13••, 14]. This review will focus on the key exper-
iments and clinical evidence, including development of novel
diagnostic methods which we believe can, for the first time,
differentiate between heart disease in T1D and T2D. We be-
lieve these findings provide a conceptual shift of CVD in
T1D, which is widely viewed as the Bsame disease^ as CVD
in T2D. Finally, we will discuss the implications of this new
mechanistic framework on the development of targeted ther-
apies to improve CVD outcomes in patients with T1D.
For the purposes of this review, CVD will be defined
as coronary heart disease, the major form of CVD in
T1D patients, and will not include cerebrovascular dis-
ease or peripheral vascular disease. We will not discuss
the risk factors in T1D for atherosclerosis, the subject
of a recent excellent review [9••].
Cardiovascular Disease in Type 1 Diabetes: Scope
of the Problem
It has long been recognized that patients with T1D suffer
excess mortality from CVD, which accounts for 65–70 % of
CVD deaths [8]. CVD is notable for occurring at a younger
age in patients with T1D with the age-adjusted mortality rates
between eight and 40 times that of the general population [8,
16–18] and far exceeding that observed in T2D [8, 16]. In-
deed, a recent analysis of CVD risk in the large UK General
Practice Research Database consisting of >7,400 patients with
T1D with a mean age of 33±14.5 years and a mean T1D
duration of 15±12 years showed that CVD events occurred
on average 10–15 years earlier than age-matched non-diabetic
control subjects [19]. CVD in T1D is also notable in that
women have a paradoxically greater excess risk of death from
CVD compared to men [3, 4••], with hazard ratios of death
from CVD of 7.50 for women aged 35–49 years and 7.92 for
women aged 50–64 years versus controls [4••].
Moreover, the results from the 30-year natural history stud-
ies of T1D in the Pittsburgh Epidemiology of Diabetes Com-
plications Study highlight that despite a substantial decrease in
other diabetic complications including end-stage renal dis-
ease, long considered the major driver of CVD in T1D [20],
no concomitant reduction in morbidity and mortality from
CVD has been reported, with CVD accounting for
40 % of deaths in T1D subjects after 20 years of dis-
ease [21]. This high mortality from CVD sharply con-
trasts with the extremely low mortality from CVD
amongst young adults in the general population. These
findings are confirmed, albeit to different extents, by
several registry-based reports [3, 4••, 18, 19, 22–25].
Heart failure, one of the most severe complications of
CVD, has recently been analyzed by Lind and colleagues in
a nationwide Swedish observational study conducted on 20,
985 relatively young T1D patients (mean age at baseline,
38.6 years). During 9 years of follow-up, they observed a
30 % higher risk of heart failure for each 1 % point increment
in HbA1c, independently of MI [26••], the most frequent cause
of heart failure in the general population [27]. This study further
highlighted that men with T1D aged 41–45 years showed a
similar incidence for heart failure (2.4 per 1000 person-years)
to that in non-diabetic control subjects 15–20 years older (i.e.,
2.1 per 1000 person-years in the 55–64 year age group) [26••].
This study was the first to show that heart failure is a major
complication in relatively young patients with T1D.
More recently, this same Swedish group showed in another
National Diabetes Registry-based study of relatively young
patients with T1D (n=33,915; mean age at baseline,
35.8 years; mean follow-up, 8.0 years) a stepwise increase in
risk of death from CVD with poor glycemic control, up to a
10.5-fold greater in patients with mean HbA1C ≥9.7 % com-
pared to the general population. An unexpected finding from
this study was that even for T1D patients with good glycemic
control (mean HbA1C≤6.9 %) [4••], i.e., with HbA1C levels
within the currently recommended on-target glycemic range
[28] that was shown to confer long-term reduction in CVD
events in the DCCT/EDIC study [5], the risk of death from
CVD was still almost threefold greater than the risk in the
general population. Since this T1D population was relatively
young and did not generally have risk factors associated with
T2D (e.g., obesity or hypertension), the mechanisms account-
ing for this excess risk of death from CVD could not be ex-
plained [4••].
Although hyperglycemia has been clearly established by
the DCCT/EDIC [5] and other subsequent studies to be a
keymediator of CVD risk in T1D [4••, 23, 25], hyperglycemia
explained only a modest fraction of this overall risk and the
mechanisms underlying excessive CVD mortality had not
been defined [6]. Numerous factors related to the metabolic
effects of diabetes have been implicated [8, 29]; however,
none have been unique to T1D. This suggests that T1D bears
disease-specific features that require deeper analysis.
Type 1 and Type 2 Diabetes Are Etiologically Distinct
Despite hyperglycemia representing a shared diagnostic phe-
notype between T1D and T2D, the two diseases are etiologi-
cally distinct. Type 2 diabetes, the most common form of
diabetes, is typically diagnosed in midlife in patients who
exhibit several risk factors for CVD including obesity, dyslip-
idemia, and hypertension [1]. This early metabolic imbalance
is associated with increased peripheral insulin resistance on
target tissues (adipose tissue, liver, and muscle) and increased
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fasting glucose levels that, however, remain below the diabet-
ic limit for several years (Fig. 1a, right panel) [1, 28]. This
asymptomatic phase (Bprediabetes^) is associated with a sys-
temic innate inflammatory process that involves vessels, par-
ticularly the coronary arteries. The adipose tissue, with its
resident macrophages, and the liver are the main sources of
proinflammatory cytokines and chemokines that reduce insu-
lin sensitivity and promote the local inflammatory process
implicated in the formation of the atherosclerotic plaque [30].
The systemic innate inflammation and the early involve-
ment of vessels may explain why, in T2D, the first CVD event
often occurs before the clinical diagnosis of diabetes (Fig. 1a),
suggesting that hyperglycemia is just part of a complex sys-
temic inflammatory process, characterized by peripheral insu-
lin resistance with a relative insulin excess in the early phases
of the disease and a wide production of inflammatory mole-
cules by the adipocytes and liver (Fig. 1a) [1]. To this end,
CVD in T2D has to be considered not only as a mere
Bcomplication^ of hyperglycemia but a comorbidity that
may occur independently of the progression to overt
diabetic hyperglycemia [31].
In contrast, T1D is an autoimmune disease in which T cells
of the adaptive immune system target and destroy pancreatic
β cells, resulting in absolute insulin deficiency (Fig. 1a, left
panel) [32, 33, 65]. Type 1 diabetes most commonly presents
in childhood and adolescence, although it can occur at any
age. Intriguingly, the incidence of T1D, especially in the very
young (<5 years), has been increasing worldwide since the
middle of the twentieth century and is predicted to double over
the next decade [24, 34]. In contrast to patients with T2D, T1D
patients typically experience their first MI after several de-
cades of diabetes (Fig. 1) and there is strong evidence that
the duration of T1D is highly predictive of CVD—with an
increased risk of 34 % for every 10 years of disease and a
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Fig. 1 a Proposed pathogenesis of type 1 and type 2 diabetes as related to
the differential timelines of their associated CVD complications. HLA
human leucocyte antigen, AAb autoantibody. b Schematic of the
pathogenesis of post-infarction autoimmunity (PIA) in T1D patients and
humanized DQ8+NOD mice and how PIA is avoided in non-
autoimmune-prone (Bcontrol^) T2D patients and non-autoimmune-
prone B6 mice. NOD non-obese diabetic, B6 C57BL/6, α-MyHC α-
isoform of cardiac myosin heavy chain
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substantially higher risk for individuals diagnosed with T1D
in early childhood than for those as adults [26••]. Thus, the
burden of CVD mortality in T1D will likely substantially in-
crease in future years to come.
In humans and animal models, T1D is preceded by a state
referred to as Binsulitis^ that is recognized pathologically as
lymphocytic infiltration of pancreatic islets. Once insulitis is
established, it can be detected indirectly by screening serum
for antibodies to islet antigen components that include insulin,
glutamic acid decarboxylase 65, tyrosine phosphatase IA-2,
and more recently ZnT-8 [35]. These antibodies are present in
85–90 % of patients with newly diagnosed T1D, with the rate
of β-cell destruction occurring more rapidly at younger ages
[36]. The presence of multiple autoantibodies is particularly
predictive of high risk for developing T1D [37, 38] and has
been a useful surrogate marker of islet autoimmunity in diabe-
tes prevention trials. In T2D, autoimmune destruction ofβ cells
and expression of multiple islet autoantibodies do not occur.
A striking characteristic of T1D has been the almost exclu-
sive development of the disease in individuals who bear hu-
man leukocyte antigen (HLA) class II alleles HLA-DQ2,
HLA-DQ8, or both. These so-called high-risk alleles encode
antigen-presenting molecules that present peptides to CD4
helper T cells of the adaptive immune response. The specific
peptides presented by DQ2 and DQ8 are thought to explain
the exquisite β-cell specificity of the autoimmune attack in
T1D [32]. In addition, non-HLA genes that are associated
with more global defects in immune regulation are also re-
quired for disease development and are thought to underlie
the clustering of multiple autoimmune disorders in families
and individuals with T1D [39]. These features are mirrored
by non-obese diabetic (NOD) mice that spontaneously devel-
op T1D and express the class II antigen-presenting molecule,
I-Ag7, which is closely related to human DQ8.
HLA-DQ8-Humanized Mice Develop Premature Death
Due to Autoimmune Myocarditis
A fortuitous observation in a humanized transgenic NOD
mouse model a decade ago raised the possibility that autoim-
mune myocarditis might be included amongst the spectrum of
organ-specific autoimmune comorbidities associatedwith T1D.
Two groups including ourselves independently reported
that transgenic NOD mice expressing class II human leuko-
cyte antigen (HLA) DQ8, in place of murine I-Ag7, developed
spontaneous autoimmune myocarditis [15, 40]. The disease
process was characterized by lymphocytic infiltrates in the
myocardium, high-titer circulating IgG autoantibodies against
cardiac myosin heavy chain (hereafter, MyHC), and prema-
ture death due to congestive heart failure. Furthermore, our
group found that the severity of myocarditis paralleled the
incidence of T1D in three independently derived transgenic
lines that differed only in their levels of DQ8 expression,
suggesting that T1D and myocarditis, although clinically dis-
tinct, share common genetic pathways [15]. These findings
raised the intriguing possibility that an unrecognized form of
myocardial autoimmunity might contribute to the CVD bur-
den in T1D.
Our group has since defined the cellular and molecular
mechanisms of myocarditis in the DQ8+NODmodel and then
used this knowledge to develop sensitive and specific immu-
nological assays for the detection of myocarditis in humans
[12••, 13••]. These studies have shown evidence of an auto-
immune heart disease process in T1D patients with CVD that
are absent in T2D patients with CVD and will be discussed
below.
Myocarditis Is Mediated by Proinflammatory CD4 T
Cells Reactive Against α-MyHC
In our analysis of the earliest immune responses in myocardi-
tis in DQ8+NOD mice, we found that the first autoantibodies
to appear were against the cardiac tissue-specific α-isoform of
MyHC (α-MyHC), followed by reactivity to β-MyHC
expressed in both cardiac and skeletal muscles, and then to
other cardiac proteins [13••]. We proposed that this represent-
ed intra- and intermolecular epitope spreading and was an
indicator of disease progression, in a manner analogous to
the conversion from a single to multiple islet autoantibodies
in the progression to T1D [41, 42]. In contrast to autoanti-
bodies, CD4 T cell clones isolated from myocarditis heart
lesions of DQ8+NOD mice predominantly recognized α-
MyHC and adoptively transferred disease into immunodefi-
cient hosts, demonstrating that α-MyHC-reactive CD4 T cells
cause myocarditis [13••].
Furthermore, using newly developed ex vivo INF-γ ELIS
POTassays, autoreactive Tcell responses toα-MyHC, but not
β-MyHC, were observed in the peripheral blood of healthy
humans with markedly increased frequencies of α-MyHC-
reactive T cells detected in patients with myocarditis [13••].
These T cell findings were unexpected since α-MyHC only
constitutes a small fraction (7–10 %) of the total MyHC in
human heart tissue, and challenged longstanding notions
based on myocarditis models in mice (in which α-MyHC
constitutes >90 % of the total cardiacMyHC) that the immune
targeting of α-MyHC was due to its cardiac abundance, and
stimulated efforts to define alternative mechanisms.
Immune Targeting of the Heart Is BPre-programmed^
in the Thymus in Mice and Humans
It is now widely recognized that the thymus, and in particular,
specialized stromal cells called medullary thymic epithelial
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cells (mTECs) play the first and most important role in
preventing organ-specific autoimmune disease by their unusu-
al ability to express a wide range of peripheral tissue-specific
antigens, leading to the apoptotic elimination (Bdeletion^) of
developing Tcells strongly reactive to these self-antigens [43].
This mechanism is perhaps best illustrated by (pro)insulin in
T1D, in which decreased thymic expression of insulin is as-
sociated with increased susceptibility to T1D in humans
(IDDM2) [44], and conversely, thymic overexpression of in-
sulin prevents diabetes in NOD mice by deleting insulin-
autoreactive T cells [45].
After showing that α-MyHC was unique amongst cardiac
antigens in being absent in mTECs, we showed that the trans-
genic introduction of α-MyHC into the TECs of DQ8+NOD
mice induced Btolerance^ to cardiac myosin (i.e., with the
disappearance of T cell and humoral responses to cardiac my-
osin) and prevented myocarditis [13••]. These results
underscored an important role for impaired thymic tolerance
mechanisms and demonstrated that α-MyHC is a primary
autoantigen in myocarditis. We then showed that healthy
humans also normally lack α-MyHC expression in mTECs
and that this correlated with augmented T cell responses to
α-MyHC in the peripheral blood, particularly in DQ8+T1D
patients with heart disease. These findings suggested that hu-
manized DQ8+NOD mice and T1D patients develop parallel
forms of cardiac autoimmunity.
Role of Inflammation in Myocardial Infarction: a Double
Edged-Sword in T1D
One implication of this physiological Bhole^ in thymic self-
tolerance is that healthy individuals should be at risk for de-
veloping cardiac autoimmunity after inflammatory heart inju-
ry, especially following MI [14] (Fig. 1b). Indeed, transient
immune responses to cardiac myosin have been reported in
healthy individuals after MI, as was first described over one-
half century ago (BDressler’s syndrome^) [46].
A large body of evidence suggests that acute MI is a highly
immunostimulatory event. Following MI, signals are generat-
ed that trigger a profound innate inflammatory cascade
(Fig. 1b), with influx of dendritic cells, neutrophils, and mac-
rophages and release of proinflammatory cytokines (e.g.,
TNFα, IL-6, and IL-1) and inflammatory mediators that are
key for repair of the infarcted heart [47]. The same necrotic
signals and cytokines are also known to be powerful
maturative factors for dendritic cells, leading to upregulation
of the display of major histocompatibility complex and
costimulatory molecules and transforming them into highly
immunogenic antigen-presenting cells, capable of initiating
antigen-specific immune responses of the adaptive immune
system [48].
It has also been suggested that a timely resolution of myo-
cardial inflammation followingMI is not a default process, but
requires the coordinated activation of multiple inhibitory im-
mune pathways [49–51]. An impairment in the function of
these counter-inflammatory responses may affect the healing
process and has been implicated in the pathogenesis of ven-
tricular remodeling and heart failure following MI. This
Bdysfunctional^ healing is considered to be responsible for
several post-infarction complications including heart failure
and poorer outcomes following a MI [50]. We hypothesized
that in T1D patients with dysregulated adaptive immune re-
sponses, these post-MI autoimmune reactions might become
amplified and self-perpetuating, with extension of ischemic
injury and pathological consequences [13••, 14].
We will review in the next paragraphs a novel body of
evidence supporting such a post-MI autoimmune syndrome
in T1D, starting with experimental MI studies in NOD mice
and then moving on to studies performed in post-MI patients
with T1D.
Acute MI Induces a Chronic Post-MI Autoimmune
Syndrome in NOD Mice
Although the most frequently used MI model of T1D is the
streptozotocin-induced diabetes model [52], our group was
the first to examine outcomes ofMI in a model of autoimmune
T1D. Our studies revealed that MI in NOD mice—but not in
control B6 mice—induced the appearance of dense lympho-
cytic myocardial infiltrates beginning in the infarct border
zone that normally provides a barrier to contain the post-MI
inflammatory response [53]. The infiltrates were notable in
having a cellular composition (mainly B220+ B lymphocytes,
CD4+ and CD8+ T cells) similar to the spontaneously arising
native insulitis lesions of NOD mice [12••]. These findings
suggested that similar pathologic processes underlie T1D
and post-MI autoimmunity in T1D. Moreover, there was vis-
ible and histological evidence of infarct expansion and edema,
suggesting that the lymphocytic infiltrates exerted cytotoxic
effects and impaired normal scar formation. Over time, the
infiltrates extended into areas remote from the infarct zone,
with evidence of adverse ventricular remodeling and cardiac
enlargement. These findings sharply contrasted with post-MI
B6 hearts that showed the expected dense scars and were
devoid of infiltrates [12••].
In addition, following MI NOD mice—but not B6 mice—
developed high-titer autoantibodies to MyHC and a second
cardiac protein, α-actinin 2, a major component of the cardiac
z-disc. This post-infarct autoimmune (PIA) syndrome was
also characterized by expansion of γ-interferon-producing
CD4 T cell responses to α-MyHC (Fig. 1b), similar to the T
cell responses observed in DQ8+NOD mice with spontaneous
myocarditis [12••].
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We further demonstrated in humanized DQ8+NOD mice
that induction of thymic tolerance to α-MyHC eliminated
the anti-cardiac immune targeting and thus the development
of PIA and enabled normal infarct healing to occur [12••].
This α-MyHC-driven immune response suggested a potential
role for antigen-specific tolerance strategies as a possible ther-
apy for T1D patients following MI.
Development of Novel Immunoassays for Cardiac
Autoantibody Detection in Human T1D
The development of PIA in NOD mice and its augmentation
in DQ8+NOD mice stimulated efforts to determine whether a
similar PIA syndrome occurred in T1D patients. However, it
soon became apparent that reliable, standardized assays for
measuring cardiac autoantibodies were not available, with
most laboratories reliant on cadaveric human heart tissues as
a source of antigen and some cardiology groups still using
indirect immunofluorescence on human heart tissue sections
for autoantibody detection, reminiscent of the first islet cell
autoantibody assays for T1D four decades ago [54]. In addi-
tion, although Western blotting and ELISA techniques were
both reliable for MyHC autoantibody detection in NODmice,
we found that human serum performed poorly in these Bsolid-
phase^ assay formats with a high false-positivity in serum
from healthy control subjects [12••]. Modeling on the success
of fluid-phase islet antibody assays that are the gold-standard
assay format for diagnosing T1D and for identifying individ-
uals at risk of developing T1D in clinical prevention trials
[55], we developed similar radioimmunoprecipitation assays
using in vitro transcribed and translated cDNAs encoding full-
length (FL) human α-MyHC (MYH6), FL β-MyHC
(MYH7)—the majorMyHC isoform expressed in human heart
ventricle—human α-actinin 2 (ACTN2), and cardiac troponin
I (TNNI3). With these assays combined, we found that
67 % (12/18) positive control myocarditis patients ver-
sus 3/78 (4 %) healthy control sera tested positive,
achieving a sensitivity and specificity superior to previ-
ously described methods for myocarditis detection [56].
Cardiac Autoantibody Expression Profiling Differentiates
CVD in T1D from T2D
Indeed, using these newly developed assays, we found that
T1D patients examined several years following MI (average
time of sampling, 4.5 years after a MI) showed persistent titers
of cardiac autoantibodies in 15 of 18 (83 %) of cases [12••].
Conversely, the autoantibodies were detectable in only three
of 20 (15 %) post-MI T2D patients and three of 78 (4 %)
healthy control subjects (T1D post-MI vs T2D post-MI, P=
0.0001; T1D post-MI vs healthy controls, P<0.0001) with the
post-MI T2D population showing autoantibody responses in-
distinguishable from healthy controls, P=ns).
Of note, we further identified Bmyocarditis signatures^
(i.e., dual autoantibody reactivity to both α- and β-MyHC)
between post-MI T1D patients and acute myocarditis patients
without T1D or MI that were absent post-MI T2D patients
[12••]. Although immune profiling has been extensively used
in clinical oncology to subclassify cancers [57], this was the
first application of this approach to subclassify CVD in
diabetes.
Novel Use of Cardiac MRI Techniques to Assess
Myocardial Inflammation in T1D Patients with Suspected
PIA
Over the past two decades, cardiac MRI (CMR) has emerged
as the reference standard for measuring left ventricular struc-
ture, function, and infarct size [58] that are major predictors of
post-MI mortality in the general population [59, 60]. In addi-
tion, CMR has emerged as the primary non-invasive tech-
nique for assessment of myocardial inflammation in non-
diabetic patients with suspected myocarditis [61].
The EDIC study was the first to use CMR to evaluate car-
diac function in a large-scale T1D cohort [62•]. Unexpectedly,
the prevalence of myocardial scar was only 4.3 % (32 of 741
subjects) and was found in only 19 % of patients with a clini-
cally adjudicated MI. Interestingly, amongst the 713 EDIC
participants with no evidence of clinical MI, 21 showed
CMR-defined myocardial scars; the great majority of which
(14 of 21, 67 %) were of a non-ischemic rather than an
ischemic pattern. Although myocardial inflammation was
not assessed in this study, non-ischemic scar is a character-
istic CMR feature of myocarditis and other inflammatory
cardiomyopathies [61].
Our immune profiling studies suggested a chronic myocar-
ditis in a subset of post-MI T1D patients. We therefore tested
the feasibility of using cardiac MRI to detect myocardial in-
flammation in one such patient [12••]. This index case had a
history of unexplained decline in cardiac function following a
relatively small MI, 6 years prior to enrolling in our study, and
was positive for multiple cardiac autoantibodies (including α-
and β-MyHC). Cardiac MRI with the conventional contrast
agent (gadolinium) showed markedly elevated T2 signal in-
tensity, consistent with myocardial edema from myocarditis.
Myocardial inflammation was further demonstrated using the
iron-oxide nanoparticle contrast agent, ferumoxytol, which is
avidly taken by macrophages. Theses CMR findings raised
the possibility that a clinically unrecognized form of chronic
myocarditis triggered by MI might contribute to the poor
CVD outcomes in T1D [12••]. These translational studies also
pointed to new targets for the diagnosis and treatment of T1D
heart disease.
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Conclusion
The discovery of post-MI chronic myocarditis syndrome in
both humanized animal models and T1D patients opens a
new perspective on the etiology, diagnosis, and treatment of
CVD in T1D. Our studies provide the first evidence of a T1D
disease-specific process, highlighting differences in the path-
ogenesis of CVD in T1D from that in T2D.
Despite dramatic improvements in CVD outcomes in the
general population, excess CVD mortality persists in T1D,
even in patients achieving Bstandard of care^, on-target
glycemic control [4••]. Given that MI is the most common
cause of heart failure and CVD death, it will be important to
perform prospective studies in larger T1D cohorts to deter-
mine the impact of cardiac autoimmunity on post-MI out-
comes including progression to heart failure. It is surprising
how little information is currently available regarding out-
comes of T1D patients following MI [7], and only recently
has it becomemore common for papers on CVD in diabetes to
distinguish between diabetes types.
Both conventional CMR and newer molecular imag-
ing modalities provide a promising approach to define
which cardiac autoantibody profiles are most predictive
of myocardial inflammation in T1D. Since chronic myo-
carditis may be a precursor of heart failure due to di-
lated cardiomyopathy [63], such information might be
used to risk-stratify T1D MI patients and identify which
patients would most likely benefit from antigen-specific
immunotherapy. It should be noted that clinical trials of
MI patients with broad-spectrum immunosuppressive
agents to mitigate the post-MI inflammatory response
have largely unsuccessful and in fact resulted in wors-
ened post-MI outcomes (with death from MI rupture
[64]) underscoring the critical short-term role of the in-
flammatory response in healing and cardiac repair [50].
Our studies provide the rationale for antigen-specific
immune tolerance approaches as a possible therapy for
patients with T1D—and potentially for other autoimmune
prone individuals in the general population—following MI.
Acknowledgments This study was funded by the American Diabetes
Association (7-11-CT-22, to MAL), National Institutes of Health grants
R01 DK072090 and HL077554 (to MAL), P30 DK36836 (to the Joslin
Diabetes Center) The Seaver Institute (to MAL), and The Albert Renold
Travel Fellowships for Young Scientists, European Foundation for the
Study of Diabetes (to AG).
Compliance with Ethics Guidelines
Conflict of Interest Myra A. Lipes and Alfonso Galderisi declare no
conflict of interest.
Human and Animal Rights and Informed Consent This article does
not contain any studies with human or animal subjects performed by any
of the authors.
Open Access This article is distributed under the terms of the Creative
Commons Attribution License which permits any use, distribution, and
reproduction in any medium, provided the original author(s) and the
source are credited.
References
Papers of particular interest, published recently, have been
highlighted as:
• Of importance
•• Of major importance
1. Authors/Task Force M, Ryden L, Grant PJ, Anker SD, Berne C,
Cosentino F, et al. ESC Guidelines on diabetes, pre-diabetes, and
cardiovascular diseases developed in collaboration with the EASD:
the Task Force on diabetes, pre-diabetes, and cardiovascular dis-
eases of the European Society of Cardiology (ESC) and developed
in collaboration with the European Association for the Study of
Diabetes (EASD). Eur Heart J. 2013;34:3035–87.
2. Harding JL, Shaw JE, Peeters A, Guiver T, Davidson S, Magliano
DJ. Mortality trends among people with type 1 and type 2 diabetes
in Australia: 1997-2010. Diabetes Care. 2014;37:2579–86.
3. Laing SP, Swerdlow AJ, Slater SD, Burden AC, Morris A, Waugh
NR, et al.Mortality from heart disease in a cohort of 23,000 patients
with insulin-treated diabetes. Diabetologia. 2003;46:760–5.
4.•• Lind M, Svensson AM, Kosiborod M, Gudbjornsdottir S, Pivodic
A, Wedel H, et al. Glycemic control and excess mortality in type 1
diabetes. N Engl J Med. 2014;371:1972–82. This large population-
based study was the first to show excess mortality due to CVD, even
in T1D patients achieving on-target glycemic control.
5. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treat-
ment and cardiovascular disease in patients with type 1 diabetes. N
Engl J Med. 2005;353:2643–53.
6. Nathan DM, Bayless M, Cleary P, Genuth S, Lachin JM, Orchard
TJ, et al. Diabetes control and complications trial/epidemiology of
diabetes interventions and complications study at 30 years: ad-
vances and contributions. Diabetes. 2013;62:3976–86.
7. Eckel RH, Eisenbarth GS. Autoimmune diabetes inflames the heart.
Sci Transl Med. 2012;4:138fs18.
8. Libby P, Nathan DM, Abraham K, et al. Report of the National
Heart, Lung, and Blood Institute-National Institute of Diabetes
and Digestive and Kidney Diseases Working Group on cardiovas-
cular complications of type 1 diabetes mellitus. Circulation.
2005;111:3489–93.
9.•• de Ferranti SD, de Boer IH, Fonseca V, Fox CS, Golden SH, Lavie
CJ, et al. Type 1 diabetes mellitus and cardiovascular disease: a
scientific statement from the American Heart Association and
American Diabetes Association. Circulation. 2014;130:1110–30.
The most comprehensive and up-to-date review on the risk factors
for CVD in T1D.
10. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868–
74.
11. Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med.
1999;340:115–26.
12.•• Gottumukkala RV, Lv H, Cornivelli L, Wagers AJ, Kwong RY,
Bronson R, et al. Myocardial infarction triggers chronic cardiac
autoimmunity in type 1 diabetes. Sci Transl Med. 2012;4:
138ra80. The first demonstration that acute MI induces chronic
myocardial autoimmunity in a humanized mouse model and pa-
tients with T1D. Shows for the first time how immune profiling
can distinguish between CVD in T1D and T2D.
Curr Diab Rep  (2015) 15:30 Page 7 of 9  30 
13.•• Lv H, Havari E, Pinto S, Gottumukkala RV, Cornivelli L, Raddassi
K, et al. Impaired thymic tolerance to alpha-myosin directs autoim-
munity to the heart in mice and humans. J Clin Invest. 2011;121:
1561–73. This manuscript is the first demonstration of impaired
central tolerance mechanisms in the pathogenesis of inflammatory
heart disease (myocarditis) in mice and humans.
14. Lv H, Lipes MA. Role of impaired central tolerance to alpha-
myosin in inflammatory heart disease. Trends Cardiovasc Med.
2012;22:113–7.
15. Taylor JA, Havari E, McInerney MF, Bronson R, Wucherpfennig
KW, LipesMA. A spontaneous model for autoimmune myocarditis
using the humanMHCmolecule HLA-DQ8. J Immunol. 2004;172:
2651–8.
16. Deckert T, Poulsen JE, Larsen M. Prognosis of diabetics with dia-
betes onset before the age of thirty-one. I. Survival, causes of death,
and complications. Diabetologia. 1978;14:363–70.
17. Secrest AM, Becker DJ, Kelsey SF, Laporte RE, Orchard TJ.
Characterizing sudden death and dead-in-bed syndrome in type 1
diabetes: analysis from two childhood-onset type 1 diabetes regis-
tries. Diabet Med. 2011;28:293–300.
18. Secrest AM, Becker DJ, Kelsey SF, Laporte RE, Orchard TJ.
Cause-specific mortality trends in a large population-based cohort
with long-standing childhood-onset type 1 diabetes. Diabetes.
2010;59:3216–22.
19. Soedamah-Muthu SS, Fuller JH, Mulnier HE, Raleigh VS,
Lawrenson RA, Colhoun HM. High risk of cardiovascular disease
in patients with type 1 diabetes in the U.K.: a cohort study using the
general practice research database. Diabetes Care. 2006;29:798–
804.
20. Hamman RF. Mortality risk in long-standing type 1 diabetes: hope
and concern. Diabetes. 2010;59:2997–8.
21. PambiancoG, Costacou T, Ellis D, Becker DJ, Klein R, Orchard TJ.
The 30-year natural history of type 1 diabetes complications: the
Pittsburgh Epidemiology of Diabetes Complications Study experi-
ence. Diabetes. 2006;55:1463–9.
22. Marfella R, Esposito K, Giunta R, Coppola G, De Angelis L,
Farzati B, et al. Circulating adhesion molecules in humans: role
of hyperglycemia and hyperinsulinemia. Circulation. 2000;101:
2247–51.
23. Livingstone SJ, Looker HC, Hothersall EJ, Wild SH, Lindsay RS,
Chalmers J, et al. Risk of cardiovascular disease and total mortality
in adults with type 1 diabetes: Scottish registry linkage study. PLoS
Med. 2012;9:e1001321.
24. Harjutsalo V, Sjoberg L, Tuomilehto J. Time trends in the incidence
of type 1 diabetes in Finnish children: a cohort study. Lancet.
2008;371:1777–82.
25. Skrivarhaug T, Bangstad HJ, Stene LC, Sandvik L, Hanssen KF,
Joner G. Long-term mortality in a nationwide cohort of childhood-
onset type 1 diabetic patients in Norway. Diabetologia. 2006;49:
298–305.
26.•• Lind M, Bounias I, Olsson M, Gudbjornsdottir S, Svensson AM,
Rosengren A. Glycaemic control and incidence of heart failure in
20,985 patients with type 1 diabetes: an observational study. Lancet.
2011;378:140–6. This is the first study to show that heart failure is a
major complication of T1D, occuring in relatively young patients
and correlating with poor glycemic control.
27. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR,
White HD, et al. Third universal definition of myocardial infarction.
Circulation. 2012;126:2020–35.
28 . Amer i can Diabe te s Assoc ia t ion Cl in i c a l P rac t i ce
Recommendations. Diagnosis and classification of diabetes
mellitus. Diabetes Care. 2013;36:S67–74.
29. Retnakaran R, Zinman B. Type 1 diabetes, hyperglycaemia, and the
heart. Lancet. 2008;371:1790–9.
30. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory
disease. Nat Rev Immunol. 2011;11:98–107.
31. Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard
BV, et al. Diabetes and cardiovascular disease: a statement for
healthcare professionals from the American Heart Association.
Circulation. 1999;100:1134–46.
32. Stadinski B, Kappler J, Eisenbarth GS. Molecular targeting of islet
autoantigens. Immunity. 2010;32:446–56.
33. Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes.
Lancet. 2014;383:69–82.
34. Gale EA. The rise of childhood type 1 diabetes in the 20th century.
Diabetes. 2002;51:3353–61.
35. Atkinson MA. The pathogenesis and natural history of type 1 dia-
betes. Cold Spring Harb Perspect Med 2012;2:1-18.
36. Ziegler AG, Nepom GT. Prediction and pathogenesis in type 1
diabetes. Immunity. 2010;32:468–78.
37. Bingley PJ, Christie MR, Bonifacio E, Bonfanti R, Shattock M,
Fonte MT, et al. Combined analysis of autoantibodies improves
prediction of IDDM in islet cell antibody-positive relatives.
Diabetes. 1994;43:1304–10.
38. Verge CF, Gianani R, Kawasaki E, Yu L, Pietropaolo M, Jackson
RA, et al. Prediction of type I diabetes in first-degree relatives using
a combination of insulin, GAD, and ICA512bdc/IA-2 autoanti-
bodies. Diabetes. 1996;45:926–33.
39. Todd JA. Etiology of type 1 diabetes. Immunity. 2010;32:457–67.
40. Elliott JF, Liu J, Yuan ZN, Bautista-Lopez N, Wallbank SL, Suzuki
K, et al. Autoimmune cardiomyopathy and heart block develop
spontaneously in HLA-DQ8 transgenic IAbeta knockout NOD
mice. Proc Natl Acad Sci U S A. 2003;100:13447–52.
41. Verge CF, Gianani R, Kawasaki E, Yu L, Pietropaolo M, Chase HP,
et al. Number of autoantibodies (against insulin, GAD or ICA512/
IA2) rather than particular autoantibody specificities determines
risk of type I diabetes. J Autoimmun. 1996;9:379–83.
52. Ziegler AG, Herskowitz RD, Jackson RA, Soeldner JS, Eisenbarth
GS. Predicting type I diabetes. Diabetes Care. 1990;13:762–5.
43. Klein L, Kyewski B, Allen PM, Hogquist KA. Positive and nega-
tive selection of the T cell repertoire: what thymocytes see (and
don’t see). Nat Rev Immunol. 2014;14:377–91.
44. Pugliese A, Zeller M, Fernandez Jr A, Zalcberg LJ, Bartlett RJ,
Ricordi C, et al. The insulin gene is transcribed in the human thy-
mus and transcription levels correlated with allelic variation at the
INS VNTR-IDDM2 susceptibility locus for type 1 diabetes. Nat
Genet. 1997;15:293–7.
45. Jaeckel E, Lipes MA, Von Boehmer H. Recessive tolerance to
preproinsulin 2 reduces but does not abolish type 1 diabetes. Nat
Immunol. 2004;5:1028–35.
46. Dressler W. A post-myocardial infarction syndrome; preliminary
report of a complication resembling idiopathic, recurrent, benign
pericarditis. J Am Med Assoc. 1956;160:1379–83.
47. MannDL.Activation of inflammatory mediators in heart failure. In:
Mann DL, editor. Heart failure, a companion to Braunwald’s Heart
Disease. Philadelphia: Saunders; 2004. p. 159–80.
48. Matzinger P. An innate sense of danger. Semin Immunol. 1998;10:
399–415.
49. Entman ML, Michael L, Rossen RD, Dreyer WJ, Anderson DC,
Taylor AA, et al. Inflammation in the course of early myocardial
ischemia. FASEB J. 1991;5:2529–37.
50. Frangogiannis NG. The inflammatory response in myocardial inju-
ry, repair, and remodelling. Nat Rev Cardiol. 2014;11:255–65.
51. Nahrendorf M, Pittet MJ, Swirski FK. Monocytes: protagonists of
infarct inflammation and repair after myocardial infarction.
Circulation. 2010;121:2437–45.
52. Bugger H, Abel ED. Rodent models of diabetic cardiomyopathy.
Dis Models Mech. 2009;2:454–66.
53. Frangogiannis NG. The immune system and cardiac repair.
Pharmacol Res. 2008;58:88–111.
 30 Page 8 of 9 Curr Diab Rep  (2015) 15:30 
54. Bottazzo GF, Florin-ChristensenA, DoniachD. Islet-cell antibodies
in diabetes mellitus with autoimmune polyendocrine deficiencies.
Lancet. 1974;2:1279–83.
55. PietropaoloM, Towns R, Eisenbarth GS. Humoral autoimmunity in
type 1 diabetes: prediction, significance, and detection of distinct
disease subtypes. Cold Spring Harb Perspect Med. 2012;2:1-18.
56. Lappe JM, Pelfrey CM, Tang WH. Recent insights into the role of
autoimmunity in idiopathic dilated cardiomyopathy. J Card Fail.
2008;14:521–30.
57. Galon J, Pages F, Marincola FM, Angell HK, Thurin M, Lugli A,
et al. Cancer classification using the Immunoscore: a worldwide
task force. J Transl Med. 2012;10:205.
58. Hundley WG, Bluemke DA, Finn JP, Flamm SD, Fogel MA,
Friedrich MG, et al. ACCF/ACR/AHA/NASCI/SCMR 2010 ex-
pert consensus document on cardiovascular magnetic resonance: a
report of the American College of Cardiology Foundation Task
Force on Expert Consensus Documents. Circulation. 2010;121:
2462–508.
59. Kwong RY, Sattar H, Wu H, Vorobiof G, Gandla V, Steel
K, et al. Incidence and prognostic implication of unrecog-
nized myocardial scar characterized by cardiac magnetic res-
onance in diabetic patients without clinical evidence of myo-
cardial infarction. Circulation. 2008;118:1011–20.
60. Wu E, Ortiz JT, Tejedor P, Lee DC, Bucciarelli-Ducci C, Kansal P,
et al. Infarct size by contrast enhanced cardiac magnetic resonance
is a stronger predictor of outcomes than left ventricular ejection
fraction or end-systolic volume index: prospective cohort study.
Heart. 2008;94:730–6.
61. Friedrich MG, Sechtem U, Schulz-Menger J, Holmvang G, Alakija
P, Cooper LT, et al. Cardiovascular magnetic resonance in myocar-
ditis: a JACC White Paper. J Am Coll Cardiol. 2009;53:1475–87.
62.• Turkbey EB, Backlund JY, Genuth S, Jain A, Miao C, Cleary PA,
et al. Myocardial structure, function, and scar in patients with type 1
diabetes mellitus. Circulation. 2011;124:1737–46. This study from
the DCCT/EDIC study group was the first to use CMR to study
cardiac stucture and function in a large well phenotyped T1D pop-
ulation. They showed a relationship between poor glycemic control
and aberrent LV function and also that only half of CMR-defined
myocardial scars were in an ischemic distribution pattern, with a
very low concordance between scar and clinical MI.
63. Cooper Jr LT. Myocarditis. N Engl J Med. 2009;360:1526–38.
64. Roberts R, DeMello V, Sobel BE. Deleterious effects of methyl-
prednisolone in patients with myocardial infarction. Circulation.
1976;53:I204–6.
65. Eisenbarth GS. Type I diabetes mellitus. A chronic autoimmune
disease. N Engl J Med. 1986;314:1360–8.
Curr Diab Rep  (2015) 15:30 Page 9 of 9  30 
